Description

Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor, designed to limit glucose reabsorption in the kidney, thereby promoting urinary glucose excretion. It has become a key compound in research on type 2 diabetes, insulin resistance, and renal glucose transport.

The Jiudian formulation offers consistent 10mg dosing, suitable for in vitro and in vivo studies focused on glycemic control, energy homeostasis, and cardiometabolic pathways.

?? This product is intended only for laboratory research. Not for human or veterinary administration.

Product Specifications

Mechanism & Research Applications

Dapagliflozin selectively inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and increasing urinary glucose excretion. In laboratory environments, this mode of action supports the following research fields:

• Experimental models of type 2 diabetes mellitus (T2DM)

• Studies on renal glucose handling and reabsorption mechanisms

• Insulin sensitivity and glycemic control research

• Comparative pharmacology of SGLT2 inhibitors

• Preclinical evaluation of cardio-renal protective strategies

Observed Effects in Research Models

In research settings, dapagliflozin has demonstrated:

• Significant reduction in postprandial and fasting glucose levels

• Weight reduction and caloric loss through glucosuria

• Improved insulin sensitivity in metabolic models

• Renoprotective markers under hyperglycemic conditions

Safety & Handling

• Intended Use: Research only – Not for clinical, diagnostic, or veterinary application

• Handling Precautions: Wear gloves, lab coat, and safety goggles

• Storage: Keep sealed and store in a dry, cool environment

• Disposal: Comply with local and institutional chemical disposal protocols

Research Use Disclaimer

This product is strictly intended for laboratory research use only. It is not approved for human or veterinary consumption. Use in clinical settings is prohibited. Handle according to institutional biosafety standards.